Stryker Corporation
General ticker "SYK" information:
- Sector: Health Care
- Industry: Medical - Devices
- Capitalization: $144.3B (TTM average)
Stryker Corporation follows the US Stock Market performance with the rate: 23.2%.
Estimated limits based on current volatility of 1.4%: low 356.01$, high 366.27$
Factors to consider:
- Earnings expected soon, date: 2026-01-29 amc
- Company included in S&P500 list
- Company pays dividends (quarterly): last record date 2025-12-31, amount 0.88$ (Y0.97%)
- Total employees count: 53000 (+1.9%) as of 2024
- US accounted for 75.0% of revenue in the fiscal year ended 2024-12-31
- Top business risk factors: Supply chain disruptions, Public health crises, Geopolitical risks, Cybersecurity threats, Regulatory and compliance
- Price in estimated range
- Earnings for 9 months up through Q3 are close to our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [327.98$, 425.83$]
- 2025-12-31 to 2026-12-31 estimated range: [353.20$, 457.09$]
Financial Metrics affecting the SYK estimates:
- Negative: with PPE of 29.9 at the end of fiscal year the price was high
- Positive: 7.54 < Operating profit margin, % of 16.33
- Positive: 42.53 < Shareholder equity ratio, % of 48.02 <= 64.17
- Negative: negative Industry operating cash flow (median)
- Positive: Inventory ratio change, % of -1.67 <= -0.76
- Positive: 0.04 < Operating cash flow per share per price, % of 3.06
- Positive: Return on assets ratio (scaled to [-100,100]) of 6.51 > 6.04
Short-term SYK quotes
Relationship graph
Long-term SYK plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $18,449.00MM | $20,498.00MM | $22,595.00MM |
| Operating Expenses | $15,608.00MM | $16,610.00MM | $18,906.00MM |
| Operating Income | $2,841.00MM | $3,888.00MM | $3,689.00MM |
| Non-Operating Income | $-158.00MM | $-215.00MM | $-197.00MM |
| R&D Expense | $1,454.00MM | $1,388.00MM | $1,466.00MM |
| Income(Loss) | $2,683.00MM | $3,673.00MM | $3,492.00MM |
| Taxes | $325.00MM | $508.00MM | $499.00MM |
| Profit(Loss)* | $2,358.00MM | $3,165.00MM | $2,993.00MM |
| Stockholders Equity | $16,616.00MM | $18,593.00MM | $20,634.00MM |
| Inventory | $3,995.00MM | $4,843.00MM | $4,774.00MM |
| Assets | $36,884.00MM | $39,912.00MM | $42,971.00MM |
| Operating Cash Flow | $2,624.00MM | $3,711.00MM | $4,242.00MM |
| Capital expenditure | $588.00MM | $575.00MM | $755.00MM |
| Investing Cash Flow | $-2,924.00MM | $-962.00MM | $-3,000.00MM |
| Financing Cash Flow | $-749.00MM | $-1,594.00MM | $-525.00MM |
| Earnings Per Share** | $6.23 | $8.34 | $7.86 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.